Commission’s Communication A renewed vision for the pharmaceutical sector Peter Korytár European...
-
Upload
horatio-morton -
Category
Documents
-
view
218 -
download
0
Transcript of Commission’s Communication A renewed vision for the pharmaceutical sector Peter Korytár European...
Commission’s Communication
A renewed vision for the pharmaceutical sector
Peter KorytárEuropean Commission – DG Environment
Uppsala, 11 November 2009
Europe has been losing ground in
pharmaceutical innovation
Shortcomings in the availability of medicines
The sector becoming more and more globalised
Scientific breakthroughs revolutionize the way
medicines are developed and prescribed
Europe’s challenges
To ensure that European citizens can increasingly
benefit from a competitive industry that generates
safe, innovative and accessible medicines
The Commission’s vision
Making further progress towards a single and
sustainable market in pharmaceuticals
Taking on the opportunities and challenges of
globalization
Making science deliver for European patients
Commission Communication COM (2008) 666
Better access to medicines for European patients
Better regulation for a more competitive industry
Safer medicines for better informed citizens: Improving safety
Empowering patients
Addressing the environmental impact
Making further progress towards a single and sustainable market in pharmaceuticals
Tackling illegal medicinal products
Preparing to combat pandemics
Strengthening international cooperation
Promoting global harmonisation
Taking on the opportunities and challenges of globalization
Supporting pharmaceutical research
Realising the promises of regenerative
medicine
Towards more personalised medicines
Making science deliver for European patients
Measures to reduce the potentially harmful
impacts of pharmaceuticals on the European
environment and public health should be
proposed
Addressing the environmental impact
FP5 ERAVMIS - Environmental Risk Assessment of Veterinary
Medicines in Sludge
REMPHARMAWATER - Ecotoxicological Assessments and
Removal Technologies for Pharmaceuticals in Wastewater
POSEIDON - Assessment of Technologies for the Removal of
Pharmaceuticals and Personal Care Products in Sewage and
Drinking Water Facilities to Improve the Indirect Potable Water
Reuse
Research projects
FP6 ERAPHARM - Environmental Risk Assessment of Pharmaceuticals
F&F - pharmaceutical products in the environment: development and
employment of novel methods for assessing their origin, fate and effects
on human fecundity
NORMAN – Network or reference laboratories for monitoring of
emerging environmental pollutants
KNAPPE – Knowledge and Need Assessment on Pharmaceutical
Products in Environmental Waters
Research projects
Review the occurrence of PPs in the aquatic environment,
their removal by water treatment processes, the regulation
currently in progress, their health and environmental
impacts, eco-pharmacostewardship and eco-
pharmacovigilance approaches
Identification of actions to limit the discharge in the
environment
http://www.knappe-eu.org/
KNAPPE project
Review effectiveness of current and potential STP processes for removal of PPs
Increase knowledge of the environmental effects of PPs
Develop intelligent testing strategies for chronic toxicity assessment
Further investigate fate of PP’s in STPs
Evaluate role of environmental monitoring in risk assessment
Evaluate practicalities of adopting a “green pharmacy”
KNAPPE project - recommendations
Evaluate effectiveness of classification schemes
Unused medicines management
Evaluate methodologies to better inform public
Evaluate need for policy framework reform
KNAPPE project – recommendations
January 2009
To review the knowledge on pharmaceuticals in
the environment
Final report in preparation
EEA workshop on Pharmaceuticals in the Environment
EQS for PPs should be defined and experience in ERA for other chemicals to be used ERA of pharmaceuticals
Consideration of eco-classification
Promotion of green pharmacy
Improvement of take back schemes
Improvement of waste water treatment
Improvement of data availability and evaluation (collection of exposure data, ERA)
EEA workshop on Pharmaceuticals in the Environment – recommendations
Holder of the marketing authorisation shall be
allowed to disseminate to the general public
certain information on medicinal products subject
to medical prescriptions
Among those information also ‘information on
the environmental impact of the medicinal
material’
Information to patient – COM (2008) 663
ENV.2010.1.2.2-2 Human health and environmental effects of
exposure to pharmaceuticals released into environment:
Improve the knowledge on risks related to human health and
ecosystems, due to the exposure to pharmaceuticals and their
derivates, which are released into the environment
The studies can include innovative measurement strategies,
sampling techniques, modelling and database building
Effects of mixtures should be considered
Research – FP7
Water Framework Directive 2000/60/EC Pollution caused by certain Dangerous Substances
Directive (2006/11/EC) Environmental Quality Standards Directive Groundwater Directive (2006/118/EC) Urban Waste Water Treatment Directive
(91/271/EEC) Drinking Water Directive (98/83/EC)
Water legislation
Ph
arm
aceu
tica
ls
pro
du
cts
are
cove
red
Regulation at Member State level: main/specific pollutants – substances posing a risk to or via the aquatic environment at basin or national level, including substances with properties which may affect steroidogenic, thyroid, reproduction or other endocrine-related functions
Regulation at EU level: standards set for 33 priority substances and 8 other pollutants (no pharmaceuticals yet), but …
Water Framework Directive
by 13/01/2011
COM should prepare a new proposal review of the list of priority substances (Annex X of WFD) as well
as corresponding standards for water, sediment and/or biota amend existing acts or to establish new legislations on control
measures
Significant risk to or via aquatic environment, including to surface waters used for drinking water
Identification of risks through Risk assessments carried out under Existing Substances
Regulation 793/93, Pesticides Directive 91/414/EEC and Biocides Directive 98/8/EC, or
Targeted risk assessment focusing only on toxicity to or via aquatic environment (REACH transitional dossiers, voluntary risk assessment), or
Review of the priority list
Simplified risk-based assessment procedure based on scientific principles and taking into account
intrinsic hazard (aquatic ecotoxicity and human toxicity via aquatic exposure route), monitoring data, and production volumes and/or use patterns
Identification of priority hazardous substances (sub-set of priority substances)
REACH – Substances of Very High Concern (SVHC) Persistent Organic Pollutants (POPs) Persistent, Bio-accumulative and Toxic substances (PBTs)
Review of the priority list
Monitoring and modelling Monitoring and modelling based prioritsation methodology based prioritsation methodology CIS WG E on priority substancesCIS WG E on priority substances
Pharmaceuticals covered
Council conclusions calling to promote mutual
cooperation between all DGs and facilitate
cooperation among MS on all aspects of AMR
Commission staff working paper in preparation as
a response to the Council conclusions:
To provide overview of ongoing activities
To identify possible areas for further action
Antimicrobial resistance (AMR)
Impact of antimicrobial excretion on the environment should be monitored
Monitoring of use of antimicrobials in veterinary medicine
Prudent use of antimicrobials
Antimicrobial resistance (AMR)
Objectives
To identify problem of endocrine disrupters, its
causes and consequences
To identify appropriate policy actions on the
basis of the precautionary principle
Strategy on Endocrine disrupters COM(1999)706
Establishment of a priority list of substances
Information exchange and international
coordination
Communication to the public
Identification and assessment of EDCs
Research and development
Legislative action
Strategy on Endocrine disrupters COM(1999)706
http://ec.europa.eu/environment/
European Commission